Dendreon (DNDN) is currently up about 17% (slightly off intraday highs of +19.5%). The pharmaceutical company has a 20% net float short and is attempting to recover from a massive gap down last Summer that came when one of its signature drugs failed to gain FDA approval. Technically, DNDN had been a tight flag pattern for most of 2012, which is what brought the stock onto my radar. DNDN had…
View the full post at http://blog.t3live.com
